50% of patients with severe asthma are not adequately controlled. Are yours?

Join Nicholas S. Hill, MD and Sucharita R. Kher, MD for a fascinating program on diagnosing and managing severe asthma. This DKBmed Talk brings the engaging TED Talk format to healthcare providers, combining poignant patient stories with the latest scientific and clinical information for a groundbreaking new symposium at CHEST 2017. See the agenda and sign up below:




Tuesday, October 31, 2017
Doors open at 5:30am
Breakfast served

Room Grand West
Sheraton Centre Hotel
123 Queen Street West
Toronto, ON Canada


Registration



Stories are part of being human; they’re the way we organize our brains. This is why the famous TED talks appeal to millions of people; they employ our most potent tools of memory and imagination to expand our minds.

DKBmed Talks now bring this engaging format to health care providers. Our expert faculty share their most poignant stories – the patients who made them appreciate why they chose to practice medicine. In addition, all the scientific and clinical details will be provided in a way you have never seen before.

Meet Seth and hear how we will tackle:

  • Differentiating between asthma and severe asthma
  • How to treat – why standard treatments fail in patients with severe asthma
  • Classifying patients’ asthma phenotype and endotype to individualize care
  • New therapeutic targets
  • Approved agents and therapies in development
  • Type 2 asthma prototype
  • Using biomarkers to address unique needs in type 2 patients
  • Using companion test to individualize therapy

Agenda
Welcome
Seth - A DKBmed Talk Part 1
Faculty Presentation
  • Differentiating between asthma and severe asthma
  • How to treat: why standard treatments fail in patients with severe asthma
  • Classifying patients’ asthma phenotype and endotype to individualize care
Seth - A DKBmed Talk Part 2
Faculty Presentation
  • New therapeutic targets: bioactive molecules and the pathophysiology of severe asthma
  • Approved agents: mepolizumab, omalizumab, reslizumab
  • Therapies in development: benralizumab, tralokinumab, lebrikizumab, dupilumab
Seth - A DKBmed Talk Part 3
Faculty Presentation
  • Type 2 asthma prototype: what it means for your patients
  • Using biomarkers to address unique needs in type 2 patients
  • Using companion diagnostic tests to individualize therapy
Audience Q&A

Faculty

  • Sucharita R. Kher, MD - Co-Course Director
  • Medical Director, Pulmonary Clinic
  • Pulmonary Attending Physician,
  • Tufts Medical Center
  • Assistant Professor of Medicine,
  • Tufts University School of Medicine
  • Boston, Massachusetts

  • Read more...
  • Nicholas S. Hill, MD - Co-Course Director
  • Chief, Pulmonary, Critical Care and Sleep Division,
  • Tufts Medical Center
  • Professor of Medicine,
  • Tufts University School of Medicine
  • Boston, Massachusetts

  • Read more...

Copyright © 2017. Tufts University School of Medicine and Severe Asthma



This symposium is not sponsored, endorsed, or accredited by the American College of Chest Physicians.